Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.

Martin K R SvačinaAnika MeißnerFinja SchweitzerAnne LadwigAlina Sprenger-SvačinaInes KleinHauke WüstenbergFelix KohleChristian SchneiderNicolai B GretherGilbert WunderlichGereon R FinkFlorian KleinVeronica Di CristanzianoHelmar Christoph Lehmann

Published in: European journal of neurology (2022)

Our study indicates that IVIg does not impair the antibody response to COVID-19 mRNA vaccine in a short-term observation, when administered a minimum of 2 weeks after each vaccine dose. The infusion of current IVIg preparations that contain anti-SARS-CoV-2 IgG does not significantly alter serum anti-SARS-CoV-2 IgG titers.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
low dose
high dose
gestational age
newly diagnosed
binding protein